Device Trial Radar · NCT05881733
Effect of a Bigger Cryoballoon on the Total Antral Lesion Size: Evaluation of POLARx FIT
Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Oct 2, 2023
Primary completion
Apr 29, 2024
Study completion Apr 23, 2025
Sponsor
- Lead sponsor
- Erasmus Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boston Scientific Corporation
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators will prospectively evaluate the extent of antral lesion created by the 31 mm balloon size of a novel cryoballoon catheter (POLARx FIT). In 20 patients with paroxysmal atrial fibrillation, the investigators will perform pre- and post-ablation high-definition 3D maps to quantify the extent of lesion created by the 31 mm POLARx FIT cryoballoon.
Conditions
- Atrial Fibrillation
Interventions
POLARx FIT cryoballoonDevice
Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Ablated Left Atrial Posterior Wall With a 31 mm Balloon Size POLARx FITTime frame: Interprocedural (directly after cryoablation)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Erasmus Medical Center
Rotterdam, South Holland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.